{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-090766","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.309658+00:00","generated_at":"2026-05-30T10:05:40.847559+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INmune Bio announces Cell Reports publication showing XPro1595 promotes remyelination","bullets":["Publication in Cell Reports demonstrates XPro1595 converts microglia from demyelinating to remyelinating cell.","Study led by Hellenic Pasteur Institute; identifies solTNF as critical checkpoint for microglia polarization.","Demyelination is core mechanism in neurodegeneration; XPro1595 targets solTNF to restore glia function.","INmune expects top-line Phase II cognitive results in early Alzheimer's patients in first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-090766","json":"https://secwatch.observer/filing/0001213900-24-090766.json","markdown":"https://secwatch.observer/filing/0001213900-24-090766.md","text":"https://secwatch.observer/filing/0001213900-24-090766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/0001213900-24-090766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/ea0218672-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:05:40.847559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}